MELATONIN

Information current as at: 1 June 2025

The pharmaceutical company has advised that it is not proceeding in the PBS listing process at this time. The process for listing this medicine has ceased.


Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Slenyto®
Pharmaceutical company:
Aspen Pharmacare Australia Pty Ltd
Condition/indication:
(therapeutic use)
  • Insomnia
PBAC Submission type:
New listing (–)
Comment:
Item was considered by PBAC between its July 2021 and November 2021 meeting. No further action, please see MELATONIN link in Related medicines below.
Related medicines:

Progress Details

Submission received for::
November 2021 PBAC meeting
Opportunity for consumer comment:
Open 28/07/2021 and close 22/09/2021 (see PBS Website)
PBAC meeting:
Held on 03/11/2021
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
14/12/2021
Lodgement of required documentation:
23/12/2021
Acceptance of complete documentation:
Not Accepted
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable

Case ID: a510

Page last updated: 31 December 2024

v.9.18